Last reviewed · How we verify
Methotrexate Toxicity — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Fusilev | Levofolinic acid | Spectrum Pharms | Folate Analog | 2008-01-01 | ||
| Fusilev | levoleucovorin | Acrotech Biopharma | Folate Analog | 2008-01-01 | ||
| Wellcovorin | leucovorin | Pfizer Japan Inc | Folate Analog | Dihydrofolate reductase | 1952-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Acrotech Biopharma · 1 drug in Methotrexate Toxicity
- Pfizer Japan Inc · 1 drug in Methotrexate Toxicity
- Spectrum Pharms · 1 drug in Methotrexate Toxicity
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Methotrexate Toxicity:
- Methotrexate Toxicity treatment updates — RSS
- Methotrexate Toxicity treatment updates — Atom
- Methotrexate Toxicity treatment updates — JSON
Cite this brief
Drug Landscape (2026). Methotrexate Toxicity — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/methotrexate-toxicity. Accessed 2026-06-10.
Related
- Methotrexate Toxicity full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing